Abbott Reports Strong Growth in First Quarter

Abbott entered 2018 with very good momentum and the first quarter’s results reflect the strong growth to come.

NO IMAGE
Strategy and Strength | Apr. 18, 2018

The first quarter is in the books – and Abbott showed strong results, positioning the company for long-term sustainable and organic growth.

For the quarter, we beat Street estimates on the top and bottom lines, and we expect to continue to deliver top-tier sales and double-digit EPS growth throughout 2018. With today's results, Abbott has met or beaten Street adjusted EPS estimates every quarter for more than 10 years.

The strong growth we delivered this quarter is a direct result of the strategic steps we've taken to position the company in the most attractive areas of healthcare and the productivity of our technologies. In the first quarter:

We continued our leadership in Cardiovascular Devices through our rapidly growing portfolio.

We continued to revolutionize how people manage their diabetes.

We continue to personalize and harmonize the lab with our diagnostics technology.

For full financials, you can read our press release, but major highlights are included in the materials below:

Abbott's Chairman and CEO Miles D. White shared his views on first-quarter performance:

Learn more about Abbott's first-quarter 2018 results:

Download a summary of Abbott's earnings highlights here:

For more information on Abbott's earnings results, see the news release.

* Finger sticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

Indications and Important Safety Information

The FreeStyle Libre Flash Glucose Monitoring system is a continuous glucose monitoring (CGM) device indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The system is intended for single patient use and requires a prescription.

CONTRAINDICATIONS:

Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS:

Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The FreeStyle Libre system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The FreeStyle Libre system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.